Journal article · 2025 · Open access
Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases
Clinical Immunology Communications, 8, 60–74 · Published 11 September 2025 · DOI 10.1016/j.clicom.2025.09.003
In brief
“Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases” is a 2025 journal article by A. M. Mukherjee, published in Clinical Immunology Communications. OpenAlex counts 5 citations as of 19 November 2026, which puts it in the top 3% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Immunology Communications.
- Citations
- 5
- Most cited in
- 2026 (5)
- Field-weighted impact
- 1.84
- References
- 125
- Authors
- 1
Abstract
Autoimmune diseases result from a breakdown in immune tolerance, leading to chronic activation of autoreactive lymphocytes. Conventional therapies offer symptomatic relief but rarely achieve durable remission. Chimeric antigen receptor (CAR)-T cell therapy, originally developed for hematologic malignancies, is now being repurposed to selectively deplete pathogenic immune subsets in autoimmunity. This review explores how CAR-T cells may not only eliminate autoreactive B and T cells but also reprogram immune homeostasis toward long-term tolerance. Recent clinical success with CD19-directed CAR-T cells in refractory systemic lupus erythematosus underscores this paradigm shift. Furthermore, next-generation constructs including dual CARs, inhibitory CARs (iCARs), and CAR-Tregs offer innovative strategies to balance cytotoxicity with regulatory control. Key challenges such as antigen escape, off-target effects, and therapeutic accessibility are critically analyzed within current translational and clinical landscapes. This work advocates for a mechanistically guided redefinition of autoimmune therapy through precision-engineered immune reprogramming. Chimeric antigen receptor-engineered T (CAR-T) cell pathways in autoimmune disease treatment, as well as the roles of autoreactive B and T cells in autoimmune illnesses. Autoreactive B and T cells, which produce autoantibodies, release inflammatory cytokines, and function as antigen-presenting cells, are the first to cause autoimmune disorders in humans. Activated T cells either participate in tissue-specific immune responses or promote more autoreactive B cell activation. By targeting B and T cells, CAR-T cells preserve immunological homeostasis and mediate local immunosuppression via soluble immunomodulatory substances and cell-cell interactions. The schematic illustrates the mechanistic framework of CAR-based immunotherapy in autoimmune diseases, highlighting the bidirectional interplay between autoreactive immune cells and engineered CAR-T/ CAR-Treg/ CAAR-T cells. Autoreactive B and T cells, upon activation via antigen presentation and co-stimulatory signals (CD80/CD86/CD28), produce pathogenic cytokines (IL-2, IL-4, IL-6, IL-10, IFN-γ) and autoantibodies, driving disease pathology. CAR-T cells selectively target autoreactive B and T cells expressing antigens such as CD19, CD20, CD38, BCMA, CD7, or CD70, inducing cytotoxicity via IFN-γ, perforin, and granzyme B. CAR-Tregs mediate immunosuppression by recognizing tissue-specific antigens and secreting regulatory cytokines (IL-10, TGF-β), maintaining immune homeostasis. Graphical Abstract: Schematic shows the direct influence of cytokines on T cells. Arrows indicate cytokine-mediated modulation of T cell behaviour. This integrative depiction underscores the translational potential of CAR-based strategies for precise immune modulation in diverse autoimmune conditions. (Illustration created in MS PowerPoint)
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mukherjee, A. M. (2025). Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases. Clinical Immunology Communications, 8, 60–74. https://doi.org/10.1016/j.clicom.2025.09.003
MLA 9
Mukherjee, A. M. “Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases.” Clinical Immunology Communications, vol. 8, 2025, pp. 60–74. https://doi.org/10.1016/j.clicom.2025.09.003.
Chicago
Mukherjee, A. M. 2025. “Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases.” Clinical Immunology Communications 8: 60–74. https://doi.org/10.1016/j.clicom.2025.09.003.
Harvard
Mukherjee, A. M. (2025) ‘Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases’, Clinical Immunology Communications, 8, pp. 60–74. doi:10.1016/j.clicom.2025.09.003.
IEEE
A. M. Mukherjee, “Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases,” Clinical Immunology Communications, vol. 8, pp. 60–74, 2025, doi: 10.1016/j.clicom.2025.09.003.
BibTeX
@article{mukherjee2025reprogramming,
title = {{Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases}},
author = {Mukherjee, A. M.},
journal = {Clinical Immunology Communications},
year = {2025},
volume = {8},
pages = {60--74},
doi = {10.1016/j.clicom.2025.09.003},
url = {https://doi.org/10.1016/j.clicom.2025.09.003}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CAR T-cell therapy
- autoimmune disease
- immune tolerance
- autoreactive B cells
- autoreactive T cells
- CD19 CAR T cells
- systemic lupus erythematosus
- CAR-Tregs
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Mukherjee, A. M. (2025). Reprogramming immunity: Emerging therapeutic frontiers and clinical trial advances of CAR-T cell therapy in autoimmune diseases. Clinical Immunology Communications, 8, 60–74. https://doi.org/10.1016/j.clicom.2025.09.003
How many times has this paper been cited?
5 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Immunology Communications: sign in and open the full text from this page.
Who wrote this paper?
A. M. Mukherjee.
What is the DOI of this paper?
10.1016/j.clicom.2025.09.003, permanently at https://doi.org/10.1016/j.clicom.2025.09.003. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.